Moderate to Severe Atopic Dermatitis Across the Lifespan: Strategies for NPs and PAs to Optimize Care at Every Age

On-demand webcast of expert faculty presentation and patient case discussion on treating moderate to severe atopic dermatitis throughout the lifespan, including key considerations for systemic therapy and patient criteria for the use of such therapies.

• Implement patient-reported outcomes into the diagnosis, severity assessment, and treatment decisions for children and adults with moderate to severe AD

• Apply available evidence to patient selection for systemic therapies for moderate to severe AD

• Develop patient-centered care strategies by involving patients in the long-term management of moderate to severe AD, considering quality of life and functional goals

Partners for Advancing Clinical Education (Partners) requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships are mitigated according to Partners policies.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships. 

Primary Author

Benjamin Ungar, MD: consultant/advisor/speaker: AbbVie, Arcutis, Botanix, Bristol Myers Squibb, Fresenius Kabi, Galderma, Johnson & Johnson, Leo Pharma, Lilly, Pfizer, Primus, Sanofi, Sun Pharma, UCB, VRG Therapeutics; researcher (paid to institution): Incyte, Rapt, Sanofi.

Katie Smiley, PA- C: consultant/advisor/speaker: Adma Biologics, Novartis.